No Data
Hong Kong stock announcement | New China Life Insurance (01336) announces profit joy, expecting a net profit attributable to mother in the first three quarters to be 18.607 billion yuan to 20.515 billion yuan, a year-on-year increase of 95% to 115%.
Livzon Pharma (01513): Injection of acetic acid pristinamycin microspheres is newly approved for the indication of 'endometriosis'...
[Hong Kong stock connect] sino biopharm (01177) granted exclusive license in mainland China from Hutchison Whampoa Biomed (02496) for anticancer drug M701.
King & Capital | Sino Biopharm (01177) announced that its subsidiary, Zhen Dai Tian Qing, has signed an exclusive license and cooperation agreement with Yu Zhi You Bio (02496), under which Zhen Dai Tian Qing obtains exclusive, sub-licensable rights to develop, register, manufacture, and commercialize M701 developed by Yu Zhi You Bio in mainland China. Zhen Dai Tian Qing will make an initial payment of approximately 0.315 billion yuan RMB and R&D milestone payments based on the progress of the development, and pay up to a maximum of 0.7 billion yuan RMB in sales milestone payments, as well as single to low double-digit annual net sales revenue.
You Jiyou Biological-B (02496.HK) entered into a license and cooperation agreement with Charoen Pokphand on M701.
Oct 8, Grangene Alliance released an announcement on Oct 7, 2024, the company (as licensor) entered into a licensing and cooperation agreement with sino biopharm (01177.HK) subsidiary Zhejiang Tianqing Pharmaceutical Group Co., Ltd. ("Zhejiang Tianqing", as licensee), granting Zhejiang Tianqing the exclusive, sublicensable license to develop, register, manufacture, and commercialize the licensed products in the licensed territory and field. Under the licensing and cooperation agreement, the company grants Zhejiang Tianqing the rights to develop the licensed products in the licensed territory and field.
Amoy Diagnostics Bio-B (02496): The M701 malignant pleural effusion Ib mid-term study data will be released at the 2024 ESMO conference.
Youcheer Youbio-B (02496) announced that the company's independently developed epithelial cell adhesion molecule and differentiation cluster 3 dual-target...
YZYBIO-B: 2024 INTERIM REPORT
Youtz Yousheng Bio-B (02496): Chen Bin was appointed as a member of the nomination committee.
Adam's Company-B (02496) issued an announcement, independent non-executive director Dr. Chen Bin was appointed as a member of the nomination committee...
No Data
